Neurolixis, Inc.

A research team specialized in the study of nervous system disorders has found that NLX-112, a serotonin 5-HT1A receptor agonist developed by Neurolixis, reversed motor deficits in a transgenic model of Spinocerebellar ataxia3 (SCA3), a rare genetic...

The United States Patent and Trademark Office (USPTO) has issued a patent on NLX-112, a drug candidate developed by Neurolixis for treatment of human movement disorders, notably levodopa-induced dyskinesia in Parkinson's disease.

Neurolixis Inc. has been awarded funds by the US Department of Defense to test its drug candidate, NLX-112, in a preclinical model of Machado-Joseph disease (MJD), a rare and disabling inherited movement disorder.

The Neurolixis lead compound, NLX-112, is at the heart of a brain imaging investigation of functionally-active serotonin 5-HT1A receptors in humans. NLX-112, a.k.a.

Neurolixis, Inc. announced the publication of scientific data demonstrating rapid and long-lasting antidepressant activity of the Company's 'biased agonist' drug candidate, NLX-101 in a robust rodent model of depression.

The US Food and Drug Administration (FDA) gave a positive response to Neurolixis' Investigational New Drug (IND) application for NLX-112.

Neurolixis launched a collaboration with the GALA® laboratory in Castres, France. GALA® is a platform of the Rapsodee/IMT Mines Albi research facility specialized in developing novel drug formulations.

A new article in the Journal of Medicinal Chemistry describes the characterization of novel selective serotonin 5-HT1A receptor biased agonists.

Neurolixis, Inc. announced the recent publication of two scientific articles demonstrating robust effects of the Company’s lead drug candidate, NLX-112, in rodent models of Parkinson’s disease.

Neurolixis Inc., a privately held biotechnology company developing therapies for disorders of the central nervous system (CNS), today announced that it had appointed Steven A.